Ponesimod is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 2 investigational indications. It is grouped under the following drug class(es): Immunosuppressants. Its therapeutic use is listed as multiple sclerosis agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Ponvory and sphingosine-1-phosphate receptor modulator. Its PubChem CID is 11363176.
Ponesimod
| CAS No | 854107-55-4 |
|---|---|
| Molecular Formula | C23H25ClN2O4S |
| Molecular Weight | 461.0 g/mol |
| Synonyms | (5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ponesimod is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 2 investigational indications.
The listed CAS number is 854107-55-4.
The listed molecular formula is C23H25ClN2O4S.
The listed molecular weight is 461.0 g/mol.
(5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one.
The source lists Ponvory and sphingosine-1-phosphate receptor modulator.